CDKN2A and glioma: Additionally, application of the IVT IF5 NP formulation was effective in improving radiotherapy outcomes in PDGFβ-driven glioma in an RCAS-PDGF-B/Nestin-Tv-a; Ink4α/Arf−/−; Pten−/− transgenic mouse model.